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Trends and associated factors of use of opioid,
heroin, and cannabis among patients for
emergency department visits in Nevada:
2009–2017
Pearl C. Kim, MHAa, Ji Won Yoo, MDb, Chris R. Cochran, PhDa, Seong-Min Park, PhDc,
Sungyoun Chun, PhDa, Yong-Jae Lee, MDd, Jay J. Shen, PhDa,
∗
Abstract
To examine trends and contributing factors of opioid, heroin, and cannabis-associated emergency department (ED) visits in Nevada.
The 2009 to 2017 Nevada State ED database (n=7,950,554 ED visits) were used. Use of opioid, heroin, and cannabis,
respectively, was identiﬁed by the International Classiﬁcation of Diseases, 9th & 10th Revisions. Three multivariable models, one for
each of the 3 dependent variables, were conducted. Independent variables included year, insurance status, race/ethnicity, use of
other substance, and mental health conditions.
The number of individuals with opioid, heroin, cannabis-associated ED visits increased 3%, 10%, and 23% annually from 2009 to
2015, particularly among 21 to 29 age group, females, and African Americans. Use of other substance (odds ratio [OR]=3.91; 95%
conﬁdence interval [CI]=3.84, 3.99; reference - no use of other substance), mental health conditions (OR=2.48; 95% CI=2.43,
2.53; reference –without mental health conditions), Medicaid (OR=1.41; 95% CI=1.38, 1.44; reference – non-Medicaid), Medicare
(OR=1.44; 95% CI=1.39, 1.49; reference – non-Medicare) and uninsured patients (OR=1.52; 95% CI=1.49, 1.56; reference -
insured) were predictors of all three substance-associated ED visits.
With a steady increase in trends of opioid, heroin, and cannabis-associated ED visits in recent years, the main contributing factors
include patient sociodemographic factors, mental health conditions, and use of other substances.
Abbreviations: ACA = Affordable Care Act, ED = emergency department, ICD-10 = International Classiﬁcation of Diseases 10h
Edition, ICD-9= International Classiﬁcation of Diseases 9th Edition, OR= odds ratio, PDMP = prescription drug monitoring program,
SEDDN = State Emergency Department Databases of Nevada, U.S. = United States.
Keywords: cannabis, emergency department, heroin, opioid, substance use
1. Introduction
The epidemic of opioid abuse and dependency over the past 2
decades creates an urgent health policy and public health concern
in the United States (U.S).[1] The volume of opioids prescribed
plateaued in 2010 but has modestly declined since then.[2] In
2016, nearly 64,000 people died from drug overdoses in the U.
S.[3] Based on current data and projections, death from opioids
will continue to increase further still in the upcoming dates.[3] The
opioid epidemic has manifested in many ways. For example, high
rates of intravenous drug use among individuals with opioid use
disorders have led to local outbreaks of hepatitis C.[4] According
to the Centers for Disease Control and Prevention, heroin-
associated deaths increased more than 4-fold increase in the U.S.
over the last 5 years.[5] The epidemic is so far-reaching that it has
been cited as a contributing factor to the declining life expectancy
of the nation.[6] While more diseases and deaths are occurring
from opioids than ever before, more states have eased regulations
on medical and recreational cannabis use. Research into the
health effects of recent state cannabis policies has shown mixed
results. Legalization of recreational cannabis in Colorado
was associated with short-term reduction in opioid-associated
deaths and medical legalization was associated with reduction in
opioid-associated hospitalizations in the U.S.[7,8] However, the
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cannabis-associated emergency department (ED) visits increased
annually by 7% in the U.S.[9] In Nevada, opioid-associated
overdose deaths have increased since 1999 and reached a rate of
13.3 deaths per 100,000 persons in 2016 which is equal to the
national rate.[10] While decrease in overdose deaths from 2011 to
2014 were detected, the number of heroin-associated deaths has
doubled from 2011 to 2016 in Nevada.[10] Nevada legalized
cannabis for medical and recreational use in 2001 and 2016.
Legal consumption of medical cannabis went into effect in 2013
and recreational consumption of cannabis went into effect in
2017. A recent study provided insight into trends of opioid and
heroin-associated inpatient and ED discharges in U.S.[11] A
decline of opioid-associated inpatient and ED discharges was
observed beginning in 2010, yet heroin-associated discharges
started a sharp increase began in 2008.[11]
A decrease of opioid-associated deaths and hospital utilizations
starting in 2010 mirrored federal initiatives urging more
judicious opioid prescribing in 2010, accompanied by an increase
trend of heroin-associated deaths and hospital utilizations. We
may speculate use of other illicit drugs such as heroin in lieu of
opioid use increases as a result of national and local polices on
opioid prescription reduction. Therefore, studying health impact
of other substance use in relation to trends of opioid in a state that
largely increase cannabis accessibility by legalizing cannabis for
medical and recreational use is important. The purpose of this
study, therefore, was 2-fold:
(1) to examine the temporal trends of opioid, heroin, and
cannabis -associated ED visits among 12 years of age or older
in the Nevada from 2009 through 2017 and
(2) to identify potential sociodemographic and other factors
associated with increased risk for those ED visits over the
same time period.
2. Methods
2.1. Data
The 2009 to 2017 State Emergency Department Databases of
Nevada (SEDDN) was used to obtain a population-based
estimate of trends. The earliest year data available are the
2009 SEDDN. The SEDDN, a de-identiﬁed dataset, contains
complete information on ED visits from all nonfederal acute
community hospitals in Nevada. All ED visits associated with use
of opioid, heroin, cannabis, other substance use, and mental
health conditions were identiﬁed by using the International
Classiﬁcation of Diseases, either the 9th Edition (ICD-9) codes
(2009 – the 3rd Quarter of 2015) or the 10th Edition (ICD-10)
(the 4th Quarter of 2015 – 2017). The speciﬁc ICD codes are
listed in the Supplemental Table, http://links.lww.com/MD/
D335. The Institutional Review Board waiver was granted by
the University of Nevada Las Vegas institutional review board for
this study. A total of 7,950,554 ED visits over the 9-year period
were included for data analysis. Since the SEDDN database
provides administrative data after a complete de-identiﬁcation,
an institutional review board approval was waived from
University of Nevada Las Vegas.
2.2. Measures and data analysis
Our 3 dependent variables were ED visits associated with use of
opioid, heroin, and cannabis, respectively. Speciﬁcally, 3 dummy
variables were respectively created, with the value of “1”
indicating “the patient associated with use of opioid, heroin, or
cannabis was treated at ED” and the value of “0” indicating “the
patient without use of opioid, heroin, or cannabis was treated at
ED” for each patient.
We formed three multivariable models, one for each of the
dependent variables. Our ﬁrst independent variable was time (an
ordinal variable with a value ranging from 1 to 9 representing the
years from 2009 to 2017, respectively). The other independent
variables included a dummy variable indicating use of other
substance(s), a dummy variable indicating the patient having a
mental health condition(s), 7 dummy variables indicating
patient’s age groups (< 12, 12 – 17, 18 – 24, 25 – 34, 35 –
44 (reference), 45 – 54, 55 – 64, and >=65), sex (a dummy
variable indicating female), health insurance status (4 dummy
variables were created to represent Medicare, Medicaid,
uninsured, and other insurance; while private insurance served
as the reference), and race/ethnicity (4 dummy variables were
created to represent African American, Hispanic/Latino, Asian
and Paciﬁc Islander, and others; while white served as the
reference). In the models for use of opioid and heroin,
respectively, use of cannabis was included as an independent
variable. In the model for use of cannabis, use of opioid was
included as an independent variable. Since use of opioid and use
of heroin were highly correlated, they were not included in each
other’s models.
We used a pooled, cross-sectional design, given that we were
unable to track individual patients. The unit of analysis was ED
visit, and multiple visits from the same patients were assumed
independent. We used the mixed model for multivariable analysis
and treated hospital as the random effect, to account for the
within hospital variations due to the clustering effect, while
estimated the ﬁxed effect of the independent variables. The
multivariable models were adjusted for hospital-level character-
istics, such as bed size, ownership type, teaching afﬁliation, and
rural or urban location. In addition, we also adjusted potential
effects of ICD coding change from the 9th Edition to the
10th Edition by using a dummy variable to indicate the
ICD-10 coding.
3. Results
The number of opioid, heroin, and cannabis -associated ED visits
increased dramatically from 73,262 in 2009 to 1,070,747 in
2017 (Table 1). Patients from 21 to 29 years old remained
relatively constant, among all age groups, as the highest risk for
opioid (37.8% in 2017), heroin (65.75% in 2017), and cannabis
(52.9% in 2017) associated ED visits. The percentage growth rate
across all 9 years varied among race/ethnicity. Findings indicated
that White patients were the most likely go to an ED for all three
substances (53.62% in 2017) while African Americans showed
the sharp increase of ED visits specially for opioid (50% increase:
8.38% in 2009 to 12.04% in 2017). Our study showed opposite
trends in associated ED visits among the uninsured andMedicaid
patients. Table 1 indicates a steep decline in opioid, heroin, and
cannabis-associated ED visits among the uninsured patients while
the annual temporal trend of Medicaid patients in associated ED
visits increased sharply. Patient characteristics of opioid, heroin,
and cannabis -associated ED visits from 2009 to 2017 are listed in
Table 1.
Figure 1 displays the annual temporal trends of the number of
ED visits and rates of with use of opioid, heroin, and cannabis per
100,000 ED visits, respectively, from 2009 to 2017. All 6 curves
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showed a trend of steady increase with a “big jump” for use of
cannabis from 428 per 100,000 ED visits in 2012 to 731 per
100,000 ED visits in 2013. From 2016 to 2017, conversely, a
decline in both opioid and cannabis- associated ED visits were
observed. In addition, similar 9-year trends were observed for the
rates of use of other substance and mental health conditions,
respectively (not shown in the ﬁgure).
We also found some signiﬁcant trends of sociodemographic
factors related disparities in ED visits associated with use of
opioid and heroin (Fig. 2). Trends of racial/ethnic disparities were
found in opioid-associated ED visits. There was a continuing
upward trend among Whites as the highest risk group with a
dramatic increase of African Americans during the same period of
time (180% increase; 33 per 100,000 ED visits in 2009, 92.4 per
100,000 ED visits in 2017). Health insurance related disparity
trends were depicted among heroin-associated ED visitors. The
rate of heroin uses amongMedicaid patients jumped signiﬁcantly
during the 9-year period while uninsured patients started
decreasing in 2013 (Fig. 2).
We found an important trend in odds of ED visits associated
with use of different substances. On average, the likelihood of
visiting EDwith opioid, heroin, and cannabis use increased about
3%, 10%, and 23% annually, respectively, from 2009 to 2017 in
Nevada (Table 2). Furthermore, patients using cannabis were
more likely to seek for opioid-associated ED treatment than their
non- cannabis use counterparts (OR=2.78; 95% CI=2.67,
2.90), in other ways, patients using opioid were more likely to
visit ED with the use of cannabis than non-opioid use counter-
parts (OR=2.68; 95% CI=2.57, 2.80). Using other substances
was a strong predictor of opioid (OR=6.68; 95% CI=6.54,
6.82), heroin (OR=3.81; 95% CI=2.87, 5.06), and cannabis
-associated ED visits (OR=3.91; 95% CI=3.84, 3.99). Finally,
patients with mental health conditions were 1 to 2 times more
likely to seek ED treatment for opioid (OR=1.73; 95% CI=
1.69, 1.77) and cannabis (OR=2.48; 95% CI=2.43, 2.53) than
patients without mental health conditions (Table 2).
Two highest risk groups of using opioid, heroin, and cannabis
among all age groups were those groups between the ages of 18 to
24 and 25 to 34. In regard to patients’ insurance status, patients
with Medicaid, Medical, and uninsured are more likely to go to
the ED for opioid, heroin, and cannabis than patients with private
insurance Medicare patients, as compared with non-Medicare
patients (OR=2.26; 95% CI=2.19, 3.14), Medicaid patients,
compared with non-Medicaid patients (OR=1.68, 95% CI=
1.64, 1.73), and uninsured patients, compared with insured
patients (OR=1.46; 95% CI=1.42, 1.50), were 126%, 68%,
and 46% more likely to visit ED for opioid use, respectively
(Table 2). While African American patients were 45% more
likely to seek ED treatment for cannabis (OR=1.45; 95% CI=
1.42, 1.48) than White patients, White patients were more likely
to go to ED than other minority groups in use of opioid, heroin,
and cannabis (Table 2).
4. Discussion
It is important to consider the potential impact of higher ED visits
in Nevada given the recent changes in laws pertaining to legal
medical and recreational cannabis use when considering the
Table 1
Patient characteristics of opioid, heroin, and cannabis associated emergency department visits in Nevada, 2009, 2013, 2017.
Opioid-associated ED visits Heroin-associated ED visits Cannabis-associated ED visits Total ED visits
2009 2013 2017 2009 2013 2017 2009 2013 2017 2009 2013 2017
N 2901 4588 8212 148 201 403 1981 5383 14,270 73,262 859,820 1,070,747
Age groups
12-17 0.97 0.78 0.38 0 0 0 0.05 0.06 0.17 18.47 16.84 15.17
18-20 3.52 2.07 0.65 4.05 1.00 0 13.53 7.56 3.73 6.09 5.29 4.85
21-24 19.06 16.94 10.25 31.76 28.36 19.35 27.66 26.16 21.28 12.34 11.96 10.64
25-29 21.13 26.79 27.57 29.05 40.30 46.40 25.29 29.15 31.62 16.47 17.15 17.52
30-34 19.65 16.46 18.64 16.22 9.95 16.38 16.71 16.98 18.18 13.87 13.28 13.56
35-44 20.89 17.44 16.39 16.89 15.42 10.92 12.67 13.06 13.07 13.15 13.28 13.56
45-64 9.89 12.05 15.43 2.03 2.99 4.96 3.58 5.57 8.37 8.54 9.56 10.81
65 and older 4.89 7.48 10.69 0 1.99 1.99 0.50 1.47 3.59 11.07 13.02 14.79
Gender
Male 53.09 50.00 50.32 72.97 74.13 69.23 64.31 61.14 58.89 46.14 45.19 45.23
Female 46.91 50.00 49.68 27.03 25.87 30.77 35.69 38.86 41.11 53.86 54.81 54.77
Race / ethnicity
White 75.18 75.92 72.99 79.73 77.61 78.16 60.58 59.19 57.13 57.87 55.04 53.62
African American 8.38 9.39 12.04 2.70 2.99 1.74 20.19 22.09 23.24 14.43 15.41 17.81
Hispanic 7.24 7.93 8.13 8.11 11.44 9.93 11.46 9.75 11.51 16.65 16.37 17.08
Asian and Paciﬁc Islander 2.38 2.66 1.25 2.03 2.99 0.99 3.03 3.23 1.58 4.38 5.00 3.58
Insurance status
Medicare 11.34 18.72 21.44 2.03 3.98 4.47 4.34 8.86 9.36 12.57 16.47 17.28
Medicaid 9.24 14.63 46.36 5.41 13.43 55.58 12.92 17.65 42.56 16.03 21.27 39.47
Private insurance 25.37 21.88 20.41 16.89 16.42 14.89 22.36 22.85 30.64 38.43 32.20 31.20
Uninsured 50.60 39.39 10.59 73.65 61.19 23.33 58.46 44.94 15.63 29.67 25.76 10.08
Comorbidity
Other substance use 25.23 26.26 71.21 26.35 36.32 45.91 42.91 35.02 39.44 4.18 5.20 13.35
Mental health disorders 9.48 17.22 26.50 5.41 7.46 11.41 19.74 19.78 26.79 3.67 5.74 9.34
Notes. Results of 2010, 2011, 2012, 2014, 2015, and 2016 are not displayed for the sake of reducing the width of the table; All numbers are expressed as a percentage except being noted; Percentages may not
add to 100 because of rounding; ED, emergency department.
Source. State Emergency Department Databases of Nevada, 2009 to 2017.
Kim et al. Medicine (2019) 98:47 www.md-journal.com
3
trends of substantial increase in cannabis -associated hospital use
based on the national data sample. This “big jump (a.k.a., level
and slope change pattern)” pattern of cannabis -associated
hospitalization was also observed from the 2 decades longitu-
dinal analysis of National Inpatient Sample (1993–2014).[12]
The impact of Medicaid expansion under the Affordable Care
Act (ACA) in 2010 showed many uninsured patients had been
covered by Medicaid.[13] A changes in payer mix between
Medicaid and uninsured patients were found in a study of
cannabis-associated ED visits in U.S. based on 2006 to 2014
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National Emergency Department Sample data.[9] A study on
complete inpatient discharge data from all nonfederal acute
care hospitals in Nevada reported the postexpansion trends
increased rapidly among Medicaid patients at the beginning of
2014.[14] Our study also observed a sharp increase
amongMedicaid patients and decrease among uninsured patients
in opioid, heroin, and cannabis associated ED visits between
2013 and 2017. It is important to note that Medicaid expansion
under provisions of the ACA was implemented in 2014
in Nevada.
Nevada residents have shown an acceptance of legalized
cannabis consumption, ﬁrst with the passage of medical cannabis
use in 2001, followed by the passage of legalized recreational
consumption afﬁrmed in 2016. While it took the state nearly 15
years to establish state-certiﬁed medical cannabis dispensaries,
much less time was needed to license and regulate recreational
cannabis dispensaries which become operational in July 2017.
Moreover, the tacit acceptance of legalization of cannabis in
some form since 2001 when medical cannabis was legalized may
have contributed to a macroscopic social diffusion, in expanding
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cannabis consumption, licitly or illicitly.[15] Medical cannabis
laws appear to have advanced social contagion of substance use
in general, contributing to a collective trend toward the passage
of recreational cannabis legalization laws, according to the three
different nationally representing U.S. adult surveys.[16] Whether a
fait accompli regarding cannabis legalization has inﬂuenced an
increase in cannabis consumption along with in combination
with opioids is unclear. It is also worth noting that states that
have not legalized cannabis in any form or beyond medical use
also have shown an increase in opioid and heroin use and hospital
admissions. Moreover, the development, marketing, prescribing
and ultimate abuse of prescription opioid also grew during this
period. Since both inﬂuencing social factors coexisted during this
period the relationship of social acceptance cannabis and the
coinciding increase in prescription opioids merits further study.
This social contagion of substance use may obviously extend to
the population of previously underuse population such as middle
age, female, Medicaid and Medicare patients in our analysis.
These populations are compatible with substantially increased
volume of degenerative orthopedic conditions/operations as well
as opioid prescription across the U.S.[17] Even so, our ﬁndings
documenting a higher use of cannabis in combination with
opiates among 18 to 24 year old and 25 to 24 year old does not
support the use of substances for degenerative orthopedic
conditions.
In order to enforce and regulate the prescribing and dispensing
of prescription drugs, prescription drug monitoring programs
(PDMP) were designed in the early 1900.[18] However,
implementation of PDMP was low until recent years. With
continuous increase in opioid mortality and scientiﬁcally proven
effectiveness of PDMP, states began to participate into enforcing
PDMP. In Nevada, PDMP was included in Senate Bill (SB) 459,
which was passed in 2015.[19] A sudden decrease in opioid-
associated ED visits at 2016 might have been an early impact of
PDMP implementation in Nevada.
In Nevada, recreational cannabis use was legalized in 2016.
Decrease in cannabis-associated ED visits from 2016 and 2017
from our study supports earlier study on cannabis-associated ED
visits in U.S.[9] Shen & collogues speculated that increase in
prevalence of cannabis-associated ED visits was not associated
with legalization of recreational cannabis use.[9] Hence, we may
suspect that a decrease in cannabis-associated ED visits from
2016 and 2017 might be related to recreational legalization in
2016. However, more studies need to be done to ﬁnd out impact
of recreational cannabis legalization on healthcare outcomes
associated with cannabis use and other substance use.
According to the recent national poll on older adults’
experiences, half of responders reported that they reserved
leftover opioidmedications for future use.[20] Opioid medications
that fall into the wrong hands may place family members,
particularly adolescents and young adults, and communities at
risk. Moreover, older adults often need changes to their
medications, and the use of leftover medications even occasion-
ally and without medical supervision could lead to possible
adverse drug effects. Among retirement-age adults, the poor as
well asMedicaid enrollees were disproportionate users of opioids
Table 2
Factors associated with use of opioid, heroin, and cannabis among emergency department visits in Nevada, 2009 to 2017.
Opioid Heroin Cannabis
Independent Variable OR 95% CI P value OR 95% CI P value OR 95% CI P value
Year, increment 1.03 [1.027, 1.039] <.001 1.10 [1.01, 1.20] .026 1.23 [1.22, 1.24] <.001
Opioid 2.68 [2.57, 2.80] <.001
Cannabis 2.78 [2.67, 2.90] <.001 1.07 [0.50, 2.32] <.001
Age groups
35–44 (Reference)
12-17 0.15 [0.14, 0.17] <.001 0.05 [0.00, 27.58] .350 0.05 [0.04, 0.07] <.001
18-20 0.80 [0.73, 0.87] <.001 2.87 [0.35, 23.40] .326 8.57 [6.59, 11.16] <.001
21-24 2.77 [2.64, 2.91] <.001 35.37 [7.34, 170.34] <.001 12.45 [11.74, 13.21] <.001
25-29 2.83 [2.71, 2.96] <.001 28.53 [5.98, 136.07] <.001 9.07 [8.55, 9.63] <.001
30-34 2.23 [2.13, 2.34] <.001 12.82 [2.64, 62.22] .002 6.65 [6.26, 7.05] <.001
45-64 2.21 [2.31, 2.31] <.001 9.66 [1.99, 46.98] .005 4.89 [4.61, 5.19] <.001
65 and older 2.30 [2.20, 2.41] <.001 6.39 [1.26, 32.3] .025 3.62 [3.40, 3.85] <.001
Sex
Male (Reference)
female 0.91 [0.90, 0.93] <.001 0.33 [0.25, 0.44] <.001 0.51 [0.51, 0.51] <.001
Race / Ethnicity
White (Reference)
African American 0.45 [0.44, 0.47] <.001 0.15 [0.08, 0.29] <.001 1.45 [1.42, 1.48] <.001
Hispanic 0.50 [0.48, 0.51] <.001 0.39 [0.25, 0.60] <.001 0.72 [0.71, 0.74] <.001
Asian and Paciﬁc Islander 0.42 [0.39, 0.45] <.001 0.31 [0.11, 0.86] .025 0.66 [0.62, 0.70] <.001
Insurance Status
Private insurance (Reference)
Medicare 2.26 [2.19, 2.34] <.001 1.47 [0.70, 3.07] .306 1.44 [1.39, 1.49] <.001
Medicaid 1.68 [1.64, 1.73] <.001 2.39 [1.61, 3.55] <.001 1.41 [1.38, 1.44] <.001
Uninsured 1.46 [1.42, 1.50] <.001 3.07 [2.11, 4.46] <.001 1.52 [1.49, 1.56] <.001
Comorbidity
Other substance use 6.68 [6.54, 6.82] <.001 3.81 [2.87, 5.06] <.001 3.91 [3.84, 3.99] <.001
Mental health disorders 1.73 [1.69, 1.77] <.001 0.82 [0.52, 1.28] .376 2.48 [2.43, 2.53] <.001
Notes. The multivariable analyses were adjusted for the International Classiﬁcation of Diseases systems and hospital characteristics; CI= conﬁdence interval, OR= odds ratio.
Source. State Emergency Department Databases of Nevada.
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(both prescribed and illicit) out of perceived necessity rather than
out of choice according to the nationally representing Health and
Retirement Study.[21]
Social contagion of substance use expands its impact from
single substance to polysubstance use that might have occurred
from gateway or corner stone drug (for example, cannabis) to
hard drug such as heroin.[15] In our analysis, individuals with
mental health conditions are more likely to have both opioid and
cannabis -associated ED visits. Individuals with mental health
conditions are more vulnerable to these dynamics of advancing to
polysubstance use.[22] Thus, approximately 7.9 million adults
had co-occurring mental health conditions and substance use
disorders in 2014.[23] These populations remain at risk of serious
adverse health outcomes by either or both mental health or
substance use disorders. An estimated 1.6 million patient with
substance use disorder have gained access to health care in
Medicaid expansion states.[24] Considerable gaps remain in
health care access among substance use disorder patients,
especially, with mental health conditions based on the decision
of some states to forgo Medicaid expansion.
In conclusion, Nevada residents have shown an acceptance of
legalized cannabis consumption during the last 16 years. The tacit
acceptance of legalization of cannabis in some form since 2001
when medical cannabis was ﬁrst legalized may have contributed
to a macroscopic social diffusion, in expanding cannabis
consumption, licitly or illicitly.
We must also advise that poly-substance abuse is not a new
problem. Research going back decades has documented poly-
substance abuse among drug and alcohol abusers and individuals
with mental illness.[25] Previous research shows that while
cannabis may lead to use and abuse of other legal and illegal
substances other substances such as alcohol and nicotine have led
to similar results.[26] Whether these factors may have a biological
association, other factors including one’s social environment and
interacting with others who use drugs increases their risk of
furthering their drug abuse. What may be further compounding
the relationship of opioids and cannabis use is the availability of
prescription opiates drugs which has created a new market of
drugs that can be abused. Increase in the prescription of
amphetamines and barbiturates led to abuse among individuals
for whom those drugs were not intended. The bigger challenge for
medical professionals, public health providers and policy makers
is understanding early on the potential pharmaceuticals intended
for providing relief from medical disorders and the unintended
consequences of abuse of these drugs, the development of a new
black market for these drugs and the manufacture of illicit, more
dangerous, substances that provide similar effects.
At the same time, it is important to recognize the social
determinants for substance abuse and how these affect the health
care delivery and the need for improved access for substance
abuse treatment beyond the hospital ED.
5. Limitations
Several limitations should be considered in the interpretation of
this study. First, data received was de-identiﬁed and therefore
data were assumed as cross-sectional. If patients could be tracked
over time, potential for additional patterns to emerge. Second, the
coding accuracy of opioid-associated conditions as well as
transition stability from the ICD-9 to ICD-10 systems remains
relatively low.[27,28] The jump from 2014 to 2015 might be
partially due to the change from the ICD-9 to the ICD-10 systems
because the ICD-9 coding system may have missing cases of
opioid-associated conditions than new ICD-10 coding system.[28]
However, we did adjust the potential coding effect of using the
ICD-10 in the multivariable analyses. Third, the state of Nevada
may not perfectly represent the west or southwest region where
most of these states adopted cannabis legalization but may have
different political, social, and economic atmospheres. Despite
these potential limitations, we believe this is the ﬁrst study to
report several new insights to the current. To the best of our
knowledge, there was no previous study that examined the trends
of opioid, heroin, and cannabis simultaneously and examined
associated factors of health outcomes.
6. Public health implications
Our study observed signiﬁcant changes in payer mix for all 3
drugs-associated ED visits as other studies on ED visits reported,
that is, uninsured patients shifted toward Medicaid, which might
be related to the implementation of ACA in 2010 and the
Medicaid expansion in 2014.[9,13] This pattern was more notable
in heroin-associated ED visit. This can be speculated by:
(1) the heroin’s hard (or advanced) drug characteristics that
might lead heroin user to easily depleting or already depleted
in socioeconomic status;
(2) Nevada’s unemployment rate soared and sustained higher
than the national average unemployment rate since the Great
Recession in 2008.[29]
Our study noted that African American group was the fasted
growing race/ethnicity group of opioid-associated ED visit and
was the highest probable race/ethnicity group of cannabis
-associated ED visit. These ﬁndings were in line with African
American population’s treatment and healthcare use demand in
the nationally representing databases from the Treatment
Episode Data Set, substance-involved admissions to treatment
facilities, the National Survey on Drug Use and Health, and
National Inpatient Sample.[30–32] Black race was studied to have
an increased prevalence of blunt smoking, and blunt smoking
was known to be positively associated with cannabis use and its
disorders.[31] In-depth research efforts for African American
population are warranted to inform the development of evidence-
based and culturally appropriate addiction prevention and
treatment approaches.
Considering the nation’s opioid epidemic, to reducemisuse and
abuse of prescribed opioids, more than 30 states have
implemented PDMP during the past 2 decades. Yet, PDMPs
have not been effective in reducing drug overdose mortality
rates.[33] As such, PDMPs may not be effective to comprehen-
sively address prescription diversions, doctor shopping, or other
abusive behaviors of other than prescribed opioids.[33] At-risk
districts as well as states were concentrated in the Southeastern
states with clear rural versus urban variation.[34] Further research
has to focus on why certain states or districts are more successful
in achieving more appropriate opioid prescription rates.
Heroin injection is known to be a major route of hepatitis C
transmission, and young adults are increasingly shifting from
other opiates to heroin use due to its lower price and easier
accessibility as prescription opioids become more difﬁcult to
acquire amid concern for an epidemic of opiate addiction.[35,36]
In a nationally representing survey, 20% of 12th grades reported
that they could easily get heroin if they wanted to. In the
experience from state of Maryland, heroin-associated deaths
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could be identiﬁed more by additional sources of information,
such as toxicology results and scene investigation reports.[23,37] In
our analysis, both opioid and heroin at risk population shares the
same demographic characteristics, white and male population.
These vulnerable populations overlap at risk group of opioid-
associated in-hospital mortality analysis using the National
Inpatient Sample 1993 to 2014.[32] Given ED visit is often a
precursor of hospitalization, enhancive preventive efforts for
these populations are warranted such as hepatitis C screening
that is now limited to baby boomer cohort born between 1945
and 1964 because hepatitis C is now curative condition by direct-
acting antiviral therapy.[35,38] Another aspect of further research
is the intersection between substance use associated health
outcomes and crimes speciﬁcally, among adolescents and young
adults. The relationship between medical cannabis legalization
and fatal driving accidents under opioid inﬂuence was empirically
assessed earlier, but this assessment was too early to assess the
policy effects of medical legalization.[39] Further research is
urgently warranted to examine the effects of recreational
cannabis legalization on health outcomes as well as the varieties
of crimes and misdemeanors.
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